Take a closer look at the progress of our first-in-class therapeutics for pruritus.
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights
HD-CKD
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
VFMCRP (ex-Japan and S. Korea)2,3
VFMCRP
(ex-Japan and
S. Korea)2,3
Advanced CKD
(stages IV-V)
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
Cara Therapeutics
Notalgia Paresthetica
- Phase 1
- Phase 2
- Phase 3
- Approval
Commercial Rights:
Cara Therapeutics
Footnotes:
- KORSUVA® is indicated for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitation of Use: KORSUVA® has not been studied in patients on peritoneal dialysis and is not recommended for use in this population. Please click here for full Prescribing Information. Approved in the EU, UK, Iceland, Liechtenstein, Norway and Switzerland with the tradename Kapruvia™.
- Commercialization rights to difelikefalin in defined indications – Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang Pharmaceuticals.
- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US.
HD-CKD: Hemodialysis Chronic Kidney Disease; CKD: Chronic Kidney Disease